3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
62
Carcinoma, Hepatocellular
25
Neoplasm Metastasis
15
Rectal Neoplasms
11
Colonic Neoplasms
10
Gastrointestinal Stromal Tumors
9
Sarcoma
6
Ovarian Neoplasms
5
Osteosarcoma
5
Glioblastoma
5
Cholangiocarcinoma
5
Stomach Neoplasms
4
Melanoma
4
Liver Neoplasms
4
Sarcoma, Ewing
3
Pancreatic Neoplasms
3
Neoplasms
3
Leukemia, Myeloid, Acute
3
Esophageal Neoplasms
3
Colorectal Cancer Metastatic
3
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Rhabdomyosarcoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
Hemangiosarcoma
2
Gastrointestinal Neoplasms
2
Interventions
lenvatinib
3
Surgical Procedures, Operative
3
Fluorouracil
3
Drug Therapy
3
Oxaliplatin
2
Leucovorin
2
Gemcitabine
2
Folfox protocol
2
regorafenib
1
gemcitabine-oxaliplatin regimen
1
durvalumab
1
donafenib
1
apatinib
1
Radiotherapy
1
Hepatectomy
1
Floxuridine
1
Cryosurgery
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cirrhosis, Familial, with Pulmonary Hypertension
×
regorafenib
×
Clear all
NCT06946849
2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
76 enrolled